Cortexyme Charts New Course with Acquisition of Rare Disease Player
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the two companies will enter the rare disease space and operate under the name Quince Therapeutics.
Source: biospace.com